{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00213577",
      "orgStudyIdInfo": {
        "id": "2003/112/HP"
      },
      "organization": {
        "fullName": "University Hospital, Rouen",
        "class": "OTHER"
      },
      "briefTitle": "NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder",
      "officialTitle": "Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment"
    },
    "statusModule": {
      "statusVerifiedDate": "2015-03",
      "overallStatus": "TERMINATED",
      "whyStopped": "the study has concluded normally;",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2003-12"
      },
      "primaryCompletionDateStruct": {
        "date": "2007-09",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2007-10",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2005-09-13",
      "studyFirstSubmitQcDate": "2005-09-13",
      "studyFirstPostDateStruct": {
        "date": "2005-09-21",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2015-03-23",
      "lastUpdatePostDateStruct": {
        "date": "2015-03-24",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "leadSponsor": {
        "name": "University Hospital, Rouen",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs."
    },
    "conditionsModule": {
      "conditions": [
        "Overactive Bladder"
      ],
      "keywords": [
        "overactive neurogenic bladder"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "TRIPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 80,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "interventions": [
        {
          "type": "DRUG",
          "name": "type A botulinum toxin"
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "complete urinary continence at baseline, and days 30, 90, 180, and 360"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "number of mictions or self catheterizations a day"
        },
        {
          "measure": "number of leakages, urgency adverse events"
        },
        {
          "measure": "guarding times"
        },
        {
          "measure": "urodynamics: bladder capacity, reflex volume, residual maximal capacity detrusor pressure, flow detrusor pressure"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic\n\nExclusion Criteria:\n\n* Pregnancy\n* Bladder cancer\n* Symptomatic urinary infection",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Philippe GRISE, MD",
          "affiliation": "University Hospital, Rouen",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "CHU-Rouen",
          "city": "Rouen",
          "zip": "76031",
          "country": "France",
          "geoPoint": {
            "lat": 49.44313,
            "lon": 1.09932
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "20674149",
          "type": "DERIVED",
          "citation": "Grise P, Ruffion A, Denys P, Egon G, Chartier Kastler E. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur Urol. 2010 Nov;58(5):759-66. doi: 10.1016/j.eururo.2010.06.035. Epub 2010 Jul 3."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D053201",
          "term": "Urinary Bladder, Overactive"
        }
      ],
      "ancestors": [
        {
          "id": "D001745",
          "term": "Urinary Bladder Diseases"
        },
        {
          "id": "D014570",
          "term": "Urologic Diseases"
        },
        {
          "id": "D052776",
          "term": "Female Urogenital Diseases"
        },
        {
          "id": "D005261",
          "term": "Female Urogenital Diseases and Pregnancy Complications"
        },
        {
          "id": "D000091642",
          "term": "Urogenital Diseases"
        },
        {
          "id": "D052801",
          "term": "Male Urogenital Diseases"
        },
        {
          "id": "D059411",
          "term": "Lower Urinary Tract Symptoms"
        },
        {
          "id": "D020924",
          "term": "Urological Manifestations"
        },
        {
          "id": "D012816",
          "term": "Signs and Symptoms"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D019274",
          "term": "Botulinum Toxins, Type A"
        }
      ],
      "ancestors": [
        {
          "id": "D001905",
          "term": "Botulinum Toxins"
        },
        {
          "id": "D008666",
          "term": "Metalloendopeptidases"
        },
        {
          "id": "D010450",
          "term": "Endopeptidases"
        },
        {
          "id": "D010447",
          "term": "Peptide Hydrolases"
        },
        {
          "id": "D006867",
          "term": "Hydrolases"
        },
        {
          "id": "D004798",
          "term": "Enzymes"
        },
        {
          "id": "D045762",
          "term": "Enzymes and Coenzymes"
        },
        {
          "id": "D045726",
          "term": "Metalloproteases"
        },
        {
          "id": "D001426",
          "term": "Bacterial Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D001427",
          "term": "Bacterial Toxins"
        },
        {
          "id": "D014118",
          "term": "Toxins, Biological"
        },
        {
          "id": "D001685",
          "term": "Biological Factors"
        }
      ]
    }
  },
  "hasResults": false
}